UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

Annals of oncology, 2019-09, Vol.30 (9), p.1487-1495

2019

Volltextzugriff (PDF)

IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications

Annals of oncology, 2023-08, Vol.34 (8), p.693-702

2023

Volltextzugriff (PDF)

Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702]

Annals of oncology, 2024-05, Vol.35 (5), p.482-482

2024

Volltextzugriff (PDF)

IFOSFAMIDUM AS PALLIATIVE TREATMENT FOR ADVANCED OVARIAN CANCER: IGCS-0063 06. Ovarian Cancer

International journal of gynecological cancer, 2015-05, Vol.25 Suppl 1, p.59-59

2015

Volltextzugriff (PDF)

IFOSFAMIDUM AS PALLIATIVE TREATMENT FOR ADVANCED OVARIAN CANCER: IGCS-0063 06. Ovarian Cancer

International journal of gynecological cancer, 2015-05, Vol.25 (Supp 1), p.59-59

2015

Volltextzugriff (PDF)

2731 Impact of frailty on outcome of elderly patients treated with hormone therapy for advanced/recurrent endometrial cancer (EC)

European journal of cancer (1990), 2015-09, Vol.51, p.S541-S541

2015

Volltextzugriff (PDF)

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

European journal of cancer (1990), 2015-09, Vol.51, p.S263-S264

2015

Volltextzugriff (PDF)

2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC)

European journal of cancer (1990), 2015-09, Vol.51, p.S532-S532

2015

Volltextzugriff (PDF)

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

European journal of cancer (1990), 2012-11, Vol.48 (17), p.3140-3149

2012

Volltextzugriff (PDF)

Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S37-S37

2014

Volltextzugriff (PDF)

Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S37-S38

2014

Volltextzugriff (PDF)

1350P Phase I/II trial shows promising efficacy of nadunolimab in combination with platinum doublet as second-line therapy in patients with NSCLC

Annals of oncology, 2024-09, Vol.35, p.S853-S853

2024

Volltextzugriff (PDF)

5053 POSTER Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data

European journal of cancer (1990), 2011, Vol.47, p.S346-S346

2011

Volltextzugriff (PDF)

1447P IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Annals of oncology, 2023-10, Vol.34, p.S823-S823

2023

Volltextzugriff (PDF)

1270P IMscin001: Phase Ib dose-finding study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Annals of oncology, 2020-09, Vol.31, p.S820-S821

2020

Volltextzugriff (PDF)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

The lancet oncology, 2013-02, Vol.14 (2), p.125-133

2013

Volltextzugriff (PDF)

LBA-06IMAB362: a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii141-ii142

2016

Volltextzugriff (PDF)

LBA-06 IMAB362: a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer

Annals of oncology, 2016-06, Vol.27, p.ii141

2016

Volltextzugriff (PDF)

244MO Primary results from IMscin002: A study to evaluate patient (pt)- and healthcare professional (HCP)-reported preferences for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC

ESMO open, 2024-03, Vol.9, p.102706, Article 102706

2024

Volltextzugriff (PDF)

Phase 1 Study of IMAB362 with immunomodulation in patients with advanced gastric cancer

Annals of oncology, 2017-09, Vol.28, p.v226-v226

2017

Volltextzugriff (PDF)

Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-01

2018

Volltextzugriff (PDF)

61MO IMscin001 (part 2: randomized phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC)

Immuno-oncology technology, 2022-12, Vol.16, p.100166, Article 100166

2022

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

IFOSFAMIDUM AS PALLIATIVE TREATMENT FOR ADVANCED OVARIAN CANCER: IGCS-0063 06. Ovarian Cancer

IFOSFAMIDUM AS PALLIATIVE TREATMENT FOR ADVANCED OVARIAN CANCER: IGCS-0063 06. Ovarian Cancer

2731 Impact of frailty on outcome of elderly patients treated with hormone therapy for advanced/recurrent endometrial cancer (EC)

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC)

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC)

Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821)

1350P Phase I/II trial shows promising efficacy of nadunolimab in combination with platinum doublet as second-line therapy in patients with NSCLC

5053 POSTER Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data

1447P IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

1270P IMscin001: Phase Ib dose-finding study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

LBA-06IMAB362: a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer

LBA-06 IMAB362: a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer

244MO Primary results from IMscin002: A study to evaluate patient (pt)- and healthcare professional (HCP)-reported preferences for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC

Phase 1 Study of IMAB362 with immunomodulation in patients with advanced gastric cancer

Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I

61MO IMscin001 (part 2: randomized phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC)

220O Claudin 18.2 – a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer

220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer

Suchergebnisse filtern